United States

Manas Mishra

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Mar 07 2018

Inovalon to buy info tech firm for $1.2 billion, expands client base

Inovalon Holdings Inc said on Wednesday it would buy privately held Ability Network for $1.2 billion, as the healthcare data analytics company seeks to reduce its dependence on insurers and add more clients.

Mar 01 2018

Worst flu season to lift U.S. hospital operator results

One of the most severe flu seasons in the United States this past decade is proving to be a shot in the arm for U.S. hospital operators that have struggled with tepid patient admissions in recent quarters.

Feb 28 2018

Valeant says wait one more year for turnaround; shares fall

Valeant Pharmaceuticals , nearly two years into Chief Executive Officer Joseph Papa's turnaround plan, on Wednesday told investors earnings and revenue would drop for one more year, before a projected return to growth in 2019.

Feb 22 2018

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.

Feb 20 2018

Medtronic quarterly revenue beats, margins disappoint

Medical device maker Medtronic Plc's quarterly revenue beat analysts' expectations as new product launches drove sales across its business units, but weaker-than-expected margins clouded the earnings report.

Feb 12 2018

Axovant Sciences CEO David Hung resigns, shares tumble

Axovant Sciences Ltd's shares sank 20 percent to an all-time low on Monday after Chief Executive David Hung resigned following 10 months at the biotech firm, during which its lead drug candidate failed two key trials.

Feb 08 2018

Cardinal Health profit beats on CVS tie-up, Medtronic unit buy

Cardinal Health's quarterly profit topped analysts' estimates as the U.S. drug distributor benefited from its purchase of Medtronic Plc's patient care business and a tie-up with drugstore chain CVS Health Corp .

Feb 07 2018

Biogen stops testing Tysabri to treat stroke after study fails

Biogen Inc will stop testing established drug Tysabri for the treatment of acute ischemic stroke after it failed a mid-stage study, the U.S. drugmaker said on Wednesday.

Feb 06 2018

Allergan's profit beats; migraine drug succeeds in key study

Allergan Plc on Tuesday reported better-than-expected quarterly profit on robust demand for Botox, boosted its earnings forecast and announced positive data on one of the two migraine treatments it is developing.

Feb 05 2018

Bristol-Myers' positive cancer data still lags Merck

Bristol-Myers Squibb Co on Monday provided some positive data on its immuno-oncology drugs for the most lucrative lung cancer market but it fell short of giving clarity on its ability to compete with a rival treatment from Merck & Co Inc


  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary